The gastrointestinal pharmacology of cannabinoids: Focus on motility

Pharmacology

Volumn 90, Issue 1-2, 2012, Pages 1-10

  Abalo, Raquel ^a   Vera, Gema ^a   López Pérez, Ana Esther ^b   Martnez Villaluenga, María ^a   Martín Fontelles, María Isabel ^a  

^a UNIVERSIDAD REY JUAN CARLOS   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cannabinoid; Emesis; Gastro oesophageal reflux; Gastrointestinal motility; Gut; Ileus; Irritable bowel disease; Nausea

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; APREPITANT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR AGONIST; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; CANNABINOID DERIVATIVE; CANNABIS; CISPLATIN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DEXAMETHASONE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; INTERFERON; METHANANDAMIDE; MORPHINE; NABILONE; NABIXIMOLS; OPIATE; PHYTOCANNABINOID DERIVATIVE; SEROTONIN 3 ANTAGONIST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROSOL; CHEMICAL COMPOSITION; CHEMOTHERAPY INDUCED EMESIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG CAPSULE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; HUMAN; NAUSEA; NONHUMAN; PAIN; PARALYTIC ILEUS; PRIORITY JOURNAL; REVIEW; SPASTICITY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; CANNABINOIDS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMANS;

EID: 84862217759     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000339072     Document Type: Review

References (78)

1. Izzo AA, Coutts AA: Cannabinoids and the digestive tract. Handb Exp Pharmacol 2005; 168:573-598.
2. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R: Non-psychotropic plant can-nabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009; 30: 515-527.
3. Schicho R, Storr M: Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. Can J Gastroenterol 2011; 25: 377-383.
4. Di Marzo V, Fontana A: Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. Prosta-glandins Leukot Essent Fatty Acids 1995; 53: 1-11.
5. Di Marzo V: The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 2009; 60:77-84.
6. 2. Pharmacol Rev 2010; 62: 588-631.
7. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, Piomelli D: Formation and inactivation of endogenous can-nabinoid anandamide in central neurons. Nature 1994; 372: 686-691.
8. Glaser ST, Kaczocha M, Deutsch DG: Anan-damide transport: a critical review. Life Sci 2005; 77:1584-1604.
9. Duncan M, Davison JS, Sharkey KA: Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005; 22:667-683.
10. Aviello G, Romano B, Izzo AA: Cannabi-noids and gastrointestinal motility: animal and human studies. Eur Rev Med Pharmacol Sci 2008; 12(suppl 1):81-93.
11. Izzo AA, Sharkey KA: Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010; 126:21-38.
12. Di Marzo V, Piscitelli F: Gut feelings about the endocannabinoid system. Neurogastro-enterol Motil 2011; 23: 391-398.
13. Wright KL, Duncan M, Sharkey KA: Can-nabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inf lammation. Br J Pharmacol 2008; 153: 263-270.
14. Duncan M, Thomas AD, Cluny NL, Patel A, Patel KD, Lutz B, Piomelli D, Alexander SP, Sharkey KA: Distribution and function of monoacylglycerol lipase in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1255-G1265.
15. Prestifilippo JP, Fernández-Solari J, de la Cal C, Iribarne M, Suburo AM, Rettori V, Mc-Cann SM, Elverdin JC: Inhibition of salivary secretion by activation of cannabinoid receptors. Exp Biol Med (May wood) 2006; 231: 1421-1429.
16. Izzo AA, Camilleri M: Cannabinoids in intestinal inflammation and cancer. Pharmacol Res 2009; 60:117-125.
17. Drew WG, Miller LL, Wikler A: Effect of 9-THC on the open-field activity of the rat. Psychopharmacologia 1972; 23: 289-299.
18. Chesher GB, Dahl CJ, Everingham M, Jackson DM, Marchant-Williams H, Starmer GA: The effect of cannabinoids on intestinal motility and their antinociceptive effect in mice. Br J Pharmacol 1973; 49: 588-594.
19. Gill EW, Paton WD, Pertwee RG: Preliminary experiments on the chemistry and pharmacology of cannabis. Nature 1970; 228: 134-136.
20. Roth SH: Stereospecific presynaptic inhibitory effect of delta9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea pig. Can J Physiol Pharmacol 1978; 56: 968-975.
21. Pertwee RG: Cannabinoids and the gastrointestinal tract. Gut 2001; 48:859-867.
22. Pertwee RG, Fernando SR, Nash JE, Coutts AA: Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine. Br J Pharmacol 1996; 118: 2199-2205.
23. López-Redondo F, Lees GM, Pertwee RG: Effects of cannabinoid receptor ligands on electrophysiological properties of myenteric neurones of the guinea-pig ileum. Br J Pharmacol 1997; 122:330-334.
24. Coutts AA, Irving AJ, Mackie K, Pertwee RG, Anavi-Goffer S: Localisation of canna-binoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus. J Comp Neurol 2002; 448: 410-422.
25. Grider J R, Mahavadi S, Li Y, Qiao LY, Kuemmerle JF, Murthy KS, Martin BR: Modulation of motor and sensory pathways of the peristaltic reflex by cannabinoids. Am J Physiol Gastrointest Liver Physiol 2009; 297:G539-G549.
26. Galligan JJ: Cannabinoid signalling in the enteric nervous system. Neurogastroenterol Motil 2009; 21:899-902.
27. Boesmans W, Ameloot K, van den Abbeel V, Tack J, Vanden Berghe P: Cannabinoid receptor 1 signalling dampens activity and mi-tochondrial transport in networks of enteric neurones. Neurogastroenterol Motil 2009; 21:958-e77.
28. Hons IM, Storr MA, Mackie K, Lutz B, Pitt-man QJ, Mawe GM, Sharkey KA: Plasticity of mouse enteric synapses mediated through endocannabinoid and purinergic signaling. Neurogastroenterol Motil 2012; 24:e113-e124.
29. Abalo R, Cabezos PA, López-Miranda V, Vera G, González C, Castillo M, Fernández-Pujol R, Martín MI: Selective lack of tolerance to delayed gastric emptying after daily administration of WIN 55,212-2 in the rat. Neurogastroenterol Motil 2009; 21:1002-e80.
30. Abalo R, Cabezos PA, Vera G, Fernández-Pujol R, Martín MI: The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat. Neurogastroenterol Motil 2010; 22: 694-e206.
31. Abalo R, Cabezos PA, Vera G, López-Miran-da V, Herradón E, Martín-Fontelles MI: Cannabinoid-induced delayed gastric emptying is selectively increased upon intermittent admin ist ration in the rat: role of CB1 receptors. Neurogastroenterol Motil 2011; 23: 457-467, e177.
32. Perry RL, Williams JF, Carrig CB, Kaneene JB, Schillhorn van Veen TW: Radiologic evaluation of the liver and gastrointestinal tract in rats infected with Taeni a taeniaefor-mis. Am J Vet Res 1994; 55:1120-1126.
33. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G: Effect of del-ta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009; 156: 153-162.
34. Rohof WO, Aronica E, Beaumont H, Troost D, Boeckxstaens GE: Localization of mGluR5, GABA(B), GABA(A), and cannabi-noid receptors on the vago-vagal reflex pathway responsible for transient lower esoph-ageal sphincter relaxation in humans: an immunohistochemical study. Neurogastro-enterol Motil 2012; 24:383-e173.
35. Cui YY, D'Agostino B, Risse PA, Marrocco G, Naline E, Zhang Y, Chen HZ, Finance O, Rinaldi-Carmona M, Rossi F, Advenier C: Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. Eur J Pharmacol 2007; 573:206-213.
36. Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PL: Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 2009; 157:865-880.
37. Andrews PL, Horn CC: Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 2006; 125:100-115.
38. Parker LA, Rock EM, Limebeer CL: Regulation of nausea and vomiting by cannabi-noids. Br J Pharmacol 2011; 163:1411-1422.
39. Tramèr MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ: Cannabi-noids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001; 323:16-21.
40. Duran M, Pérez E, Abanades S, Vidal X, Sau-ra C, Majem M, Arriola E, Rabanal M, Pastor A, Farré M, Rams N, Laporte JR, Capellà D: Preliminary efficacy and safety of an oromu-cosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin Pharmacol 2010; 70:656-663.
41. Costiniuk CT, Mills E, Cooper CL: Evaluation of oral cannabinoid- containing medications for the management of interferon and ribavirin-induced anorexia, nausea and weight loss in patients treated for chronic hepatitis C virus. Can J Gastroenterol 2008; 22: 376-380.
42. Van Sickle MD, Oland LD, Ho W, Hillard CJ, Mackie K, Davison JS, Sharkey KA: Canna-binoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroen-terology 2001; 121:767-774.
43. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, Gugliel-motti V, Davison JS, Di Marzo V: Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabi-noid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 2007; 25:2773-2782.
44. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Mar-nett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310:329-332.
45. Darmani NA, Johnson JC: Central and peripheral mechanisms contribute to the anti-emetic actions of delta-9-tetrahydrocanna-binol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 2004; 488:201-212.
46. Darmani NA, Janoyan JJ, Kumar N, Crim JL: Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 2003; 75: 777-787.
47. Wang Y, Ray AP, McClanahan BA, Darmani NA: The antiemetic interaction of D9-tetra-hydrocannabinol when combined with tro-pisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav 2009; 91: 367-373.
48. Billig I, Yates BJ, Rinaman L: Plasma hormone levels and central c-Fos expression in ferrets after systemic administration of cho-lecystokinin. Am J Physiol Regul Integr Comp Physiol 2001; 281:R1243-R1255.
49. Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA: Inverse agonism of CB1 receptors potentiates LiCl-induced nausea: evidence from the conditioned gaping model in rats. Br J Pharmacol 2010; 161:336-349.
50. Vera G, Chiarlone A, Cabezos PA, Pascual D, Martín MI, Abalo R: WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cis-plat in in the rat. Life Sci 2007; 81: 468-479.
51. Cabezos PA, Vera G, Castillo M, Fernández-Pujol R, Martín MI, Abalo R: Radiological study of gastrointestinal motor activity after acute cisplatin in the rat. Temporal relationship with pica. Auton Neurosci 2008; 141: 54-65.
52. Cabezos PA, Vera G, Martín-Fontelles MI, Fernández-Pujol R, Abalo R: Cisplatin-in-duced gastrointestinal dysmotility is aggravated after chronic administration in the rat. Comparison with pica. Neurogastroenterol Motil 2010; 22:797-805, e224-e225.
53. Parker LA, Kwiatkowska M, Mechoulam R: Delta-9-tetrahydrocannabinol and cannabi-diol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 2006; 87:61-71.
54. Rock EM, Limebeer CL, Mechoulam R, Pio-melli D, Parker LA: The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) el icited by a lith ium-pa ired context in t he rat. Psychopharmacol 2008; 196: 389-395.
55. Russo EB, Burnett A, Hall B, Parker KK: Agonist properties of cannabidiol at 5-HT1a receptors. Neurochem Res 2005; 30:1037-1043.
56. Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA: Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) so-matodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 2011, DOI: 10.1111/j.1476-5381. 2011.01621.
57. Allen JH, de Moore GM, Heddle R, Twartz JC: Cannabinoid hyperemesis: cyclical hy-peremesis in association with chronic can-nabis abuse. Gut 2004; 53: 1566-1570.
58. Galli JA, Sawaya RA, Friedenberg FK: Can-nabinoid hyperemesis syndrome. Curr Drug Abuse Rev 2011; 4:241-249.
59. Choung RS, Locke GR 3rd, Lee RM, Schleck CD, Zinsmeister AR, Talley NJ: Cyclic vomiting syndrome and functional vomiting in adults: association with cannabinoid use in males. Neurogastroenterol Motil 2012; 24: 20-26, e1.
60. Després JP: Pleiotropic effects of rimona-bant: clinical implications. Curr Pharm Des 2009; 15:553-570.
61. Storr MA, Yüce B, Andrews CN, Sharkey KA: The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008; 20: 857-868.
62. Camilleri M, Katzka DA: Genetic epidemiology and pharmacogenetics in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012, E-pub ahead of print.
63. Di Marzo V, Izzo AA: Endocannabinoid overactivity and intestinal inflammation. Gut 2006; 55:1373-1376.
64. Lal S, Prasad N, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart H: Cannabis use amongst patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2011; 23: 891-896.
65. Camilleri M, Carlson P, McKinzie S, Grudell A, Busciglio I, Burton D, Baxter K, Ryks M, Zinsmeister AR: Genetic variation in endo-cannabinoid metabolism, gastrointestinal motility, and sensation. Am J Physiol Gastro-intest Liver Physiol 2008; 294:G13-G19.
66. Storr M, Emmerdinger D, Diegelmann J, Pfennig S, Ochsenkühn T, Göke B, Lohse P, Brand S: The cannabinoid 1 receptor (CNR1) 1359 G/A polymorphism modulates susceptibility to ulcerative colitis and the phenotype in Crohn's disease. PLoS One 2010; 5:e9453.
67. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG: Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 2011; 25:2711-2721.
68. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, Ferri GL, Sibaev A, Storr M, Lutz B: The endogenous cannabi-noid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209.
69. Storr MA, Keenan CM, Emmerdinger D, Zhang H, Yüce B, Sibaev A, Massa F, Buckley NE, Lutz B, Göke B, Brand S, Patel KD, Shar-key KA: Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors. J Mol Med (Berl) 2008; 86:925-936.
70. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA: Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 2009; 15:1678-1685.
71. Bashashati M, Storr MA, Nikas SP, Wood JT, Godlewski G, Liu J, Ho W, Keenan CM, Zhang H, Alapafuja SO, Cravatt BF, Lutz B, Mackie K, Kunos G, Patel KD, Makriyannis A, Davison JS, Sharkey KA: Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br J Pharmacol 2012; 165:1556-1571.
72. De Petrocellis L, Orlando P, Moriello AS, Aviello G, Stott C, Izzo AA, Di Marzo V: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf) 2012; 204:255-266.
73. Schicho R, Storr M: Topical and systemic cannabidiol improves trinitrobenzene sul-fonic acid colitis in mice. Pharmacology 2012; 89:149-155.
74. Izzo AA, Capasso R, Aviello G, Borrelli F, Romano B, Piscitelli F, Gallo L, Capasso F, Orlando P, Di Marzo V: Inhibitory effect of cannabichromene, a major non-psychotro-pic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermo-tility in mice. Br J Pharmacol 2012, DOI: 10.1111/j.1476-5381.2012.01879.x.
75. Mascolo N, Izzo AA, Ligresti A, Costagliola A, Pinto L, Cascio MG, Maffia P, Cecio A, Capasso F, Di Marzo V: The endocannabi-noid system and the molecular basis of para-ly tic ileus in mice. FASEB J 2002; 16: 1973-1975.
76. Li YY, Li YN, Ni JB, Chen CJ, Lv S, Chai SY, Wu RH, Yüce B, Storr M: Involvement of cannabinoid-1 and cannabinoid-2 receptors in septic ileus. Neurogastroenterol Motil 2010; 22: 350-e88.
77. Lin XH, Yuece B, Li YY, Feng YJ, Feng JY, Yu LY, Li K, Li YN, Storr M: A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. Neurogas-t ro enterol Motil 2011; 23: 862-e342.
78. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T: Cannabi-diol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kap-paB involvement. Neurosci Lett 2006; 399: 91-95.